The Mulligan lab investigates the innate and adaptative immune responses to pathogens and vaccines, by studying how the human body successfully reacts to vaccines and battles infections and conversely, how infectious pathogens escape immune surveillance. Our overarching goal is to translate basic scientific knowledge to support the development of effective vaccines, therapeutic products, diagnostics, and predictive markers intended for clinical use.
Since March 11, 2020, the NYU Langone Vaccine Center has been enrolling coronavirus disease (COVID-19) acute and convalescent patients in a pre-existing rapid response study for infectious disease threats with public health significance. The Mulligan lab is currently dedicating its research to provide much needed information on those individuals’ immune responses to SARS-CoV-2.
In addition to SARS-CoV-2, the Mulligan lab is conducting research on other pathogens, including Zika, influenza, Mycobacterium tuberculosis, and measles.
Mark J. Mulligan, MD
Alexandria Center for Life Science — West Tower
430 East 29th Street, 3rd Floor, Room 304
New York, NY 10016
Office: (212) 263-9410
Lab: (212) 263-0905